Could a Low-Dose drug ease debilitating long COVID fatigue?
NCT ID NCT05430152
Summary
This study tested whether a low dose of the drug naltrexone (LDN) could reduce severe fatigue and improve quality of life for people with Post-COVID Fatigue Syndrome, a form of Long COVID. In this completed Phase 2 trial, 160 participants were randomly assigned to take either LDN or a placebo pill daily for 16 weeks. Researchers measured changes in fatigue, pain, activity levels, and overall well-being to see if the treatment helped.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-VIRAL FATIGUE SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Women's Health Research Institute
Vancouver, British Columbia, V6H 3N1, Canada
Conditions
Explore the condition pages connected to this study.